analogues du glp 1 GLP-1 in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives Les analogues de GLP-1 protégeraient

Patients that maintained treatment response at Week 3 of the open label treatment phase (N=116) were eligible to be randomized to ongoing treatment with the same dose of VYVANSE (N=56) or switched to placebo (N=60) during the double-blind phase

Doreswamy, S., et al

No official human dosing standard exists, so doses should be set with a physician

The savings card programs from Novo Nordisk and Eli Lilly can bring commercially insured patients down to $25 per monthly fill, subject to monthly and annual caps

Gastaldelli A, Gaggini M, Daniele G et al (2016) Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study